Cotización AN2 Therapeutics - ANTX

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Último Precio

1.06

Postura de Compra

1.06

Postura de Venta

1.15

Volume Operado de la Acción

155,419

1.03 Rango del Día 1.06

0.87 Rango de 52 semanas 22.22

Capitalización de Mercado [m]

31.633M

Precio Anterior

1.04

Precio de Apertura

1.05

Hora

2000

1.06

(formt)

Última hora de negociación

Volumen financiero

US$ 162,239

Precio Promedio Ponderado

1.0439

Volumen promedio (3 m)

628,519

Acciones en circulación

29,842,431

Rendimiento del Dividendo

Ratio Precio/Utilidad

-0.48

Beneficio por acción (BPA)

-2.17

turnover

Beneficio neto

-64.73M

AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NT... AN2 Therapeutics Inc is a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. The initial product candidate is epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial, or NTM, lung disease. Mostrar más

Sector

Pharmaceutical Preparations

Industria

Pharmaceutical Preparations

Sitio web

www.an2therapeutics.com

Sede

Dover, Delaware, USA

Fundado

AN2 Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ANTX. The last closing price for AN2 Therapeutics was US$1.04. Over the last year, AN2 Therapeutics shares have traded in a share price range of US$ 0.87 to US$ 22.22.

AN2 Therapeutics currently has 29,842,431 shares in issue. The market capitalisation of AN2 Therapeutics is US$31.04 million. AN2 Therapeutics has a price to earnings ratio (PE ratio) of -0.48.

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung disease AN2 plans to shift focus to internal boron...

Form 4 - Statement of changes in beneficial ownership of securities

Período †	Variación(Ptos)	Variación %	Apertura	Precio Máximo	Precio Mínimo	Avg. Vol. diario	Precio Promedio Ponderado
1	0	0	1.06	1.09	1.03	112718	1.05354981	CS
4	0.015	1.43540669856	1.045	1.09	1.01	182766	1.05314516	CS
12	-1.45	-57.7689243028	2.51	3.07	0.87	628519	1.154495	CS
26	-2.04	-65.8064516129	3.1	3.185	0.87	394891	1.51197145	CS
52	-13.6	-92.7694406548	14.66	22.22	0.87	325619	3.63715942	CS
156	-15.79	-93.7091988131	16.85	23.58	0.87	166167	5.43986595	CS
260	-15.79	-93.7091988131	16.85	23.58	0.87	166167	5.43986595	CS

Volumen
% Mayores Alzas
% Mayores Bajas

Símbolo	Precio	Vol.
LASELaser Photonics Corporation	US$ 7.92 (83.33%)	68.97M
TURBTurbo Energy SA	US$ 2.75 (78.57%)	7.63M
OTRKOntrak Inc	US$ 2.76 (51.65%)	98.32M
WWWW International Inc	US$ 1.1682 (47.99%)	40.7M
PDYNPalladyne AI Corporation	US$ 2.77 (47.34%)	21.37M
VINCVincerx Inc	US$ 0.4109 (-41.13%)	10.22M
CETXCemtrex Inc	US$ 0.90 (-34.31%)	14.55M
PEVPhoenix Motor Inc	US$ 0.7011 (-33.23%)	6.66M
KXINKaixin Holdings	US$ 0.1812 (-32.01%)	24.58M
SOBRSOBR Safe Inc	US$ 6.88 (-31.88%)	973.57k
AGRIAgriFORCE Growing Systems Ltd	US$ 0.0586 (22.08%)	343.83M
NVDANVIDIA Corporation	US$ 132.89 (4.05%)	285.72M
XPONExpion360 Inc	US$ 0.0301 (-11.99%)	211.29M
VERBVerb Technology Company Inc	US$ 0.0425 (1.19%)	139.42M
SQQQProShares UltraPro Short QQQ	US$ 7.34 (-4.43%)	138.89M